PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30102427-1	2019	Buprenorphine/samidorphan combination (BUP/SAM) is an opioid system modulator being investigated as adjunctive treatment for major depressive disorder.	Buprenorphine	0-13	COMM domain containing 3	Homo sapiens	39-42	
30102427-2	2019	BUP/SAM is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist added to address the abuse and dependence potential of buprenorphine.	Buprenorphine	39-52	COMM domain containing 3	Homo sapiens	0-3	
30102427-2	2019	BUP/SAM is a fixed-dose combination of buprenorphine, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist, and samidorphan, a mu-opioid receptor antagonist added to address the abuse and dependence potential of buprenorphine.	Buprenorphine	233-246	COMM domain containing 3	Homo sapiens	0-3	
30102427-3	2019	In this study, we assessed the effect of samidorphan on the abuse potential of buprenorphine in the BUP/SAM combination in nondependent, recreational, adult opioid users (ClinicalTrials.gov ID: NCT02413281).	Buprenorphine	79-92	COMM domain containing 3	Homo sapiens	100-103	
30102427-10	2019	These findings indicate that samidorphan substantially reduces the abuse potential of buprenorphine in the BUP/SAM combination.	Buprenorphine	86-99	COMM domain containing 3	Homo sapiens	107-110